NCT06821503 2026-03-10
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
30 trialsNCT07416240 2026-02-18
Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.
Hainan Cancer Hospital
Phase EARLY_PHASE1 Recruiting
NCT05085548 2025-11-12
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
ProDa BioTech, LLC
Phase 1 Active not recruiting
NCT03889795 2025-10-20
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
University of Toledo
Phase 1 Active not recruiting
NCT05657418 2025-06-06
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT06241352 2025-05-11
Statin Addition to Chemotherapy for Advanced Pancreatic Cancer
Changhai Hospital
Phase 2 Completed
NCT04796948 2025-04-29
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04228601 2024-08-16
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Completed
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT06492941 2024-07-09
A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT06422156 2024-05-20
Nim-PC-28
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT06111274 2024-04-11
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
Abbisko Therapeutics Co, Ltd
Phase 2 Recruiting
NCT05580445 2023-11-22
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2 Unknown
NCT05916261 2023-10-26
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
Ruijin Hospital
Phase EARLY_PHASE1 Recruiting
NCT04931381 2022-08-02
Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer
Changhai Hospital
Phase 3 Unknown
NCT05438797 2022-06-30
The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
Jinling Hospital, China
Phase EARLY_PHASE1 Unknown
NCT05298020 2022-03-28
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Unknown
NCT05162118 2022-03-09
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
Zhejiang University
Phase 1/2 Unknown
NCT01303172 2021-11-10
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Immodulon Therapeutics Ltd
Phase 2 Completed
NCT05100329 2021-10-29
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04928625 2021-08-24
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03415802 2021-02-01
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
ChineseAMS
Phase 2 Completed
NCT04707118 2021-01-13
Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy
Fudan University
Phase 1 Unknown
NCT02101580 2020-10-01
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
Phase 1 Completed
NCT04482257 2020-07-22
Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04239001 2020-01-23
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase NA Unknown
NCT04217096 2020-01-03
Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients
Fudan University
Phase 4 Unknown
NCT03662035 2018-09-19
ASPC
Changzhou No.2 People's Hospital
Phase 2 Unknown
NCT02124317 2016-12-22
NAPSPAC
Chinese PLA General Hospital
Phase 2 Unknown
NCT02135822 2014-05-16
NAPGAP
Chinese PLA General Hospital
Phase 2 Unknown